Benapenem - Sihuan Pharmaceuticals
Alternative Names: Benapenum - Sihuan PharmaceuticalsLatest Information Update: 28 Jan 2026
At a glance
- Originator KBP Biosciences; Sihuan Pharmaceutical Holdings Group
- Class Anti-infectives; Antibacterials; Beta-lactams; Carbapenems
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Urinary tract infections
- No development reported Bacterial infections
- Discontinued Pyelonephritis
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for phase-I development in Bacterial-infections in China (Parenteral, Injection)
- 01 Jan 2024 Clinical development is ongoing for Urinary tract infections and Bacterial infections in China
- 01 Jan 2024 Shanghai Pharmaceuticals Holdings plans a phase III trial for complicated urinary tract infections in (Shanghai Pharmaceuticals Holding pipeline, January 2024)